Health Services Research Unit, University of Aberdeen, Aberdeen, UK.
Bristol Urological Institute, Southmead Hospital, Bristol, UK.
Health Technol Assess. 2022 Aug;26(36):1-152. doi: 10.3310/TBFZ0277.
Stress urinary incontinence is common in men after prostate surgery and can be difficult to improve. Implantation of an artificial urinary sphincter is the most common surgical procedure for persistent stress urinary incontinence, but it requires specialist surgical skills, and revisions may be necessary. In addition, the sphincter is relatively expensive and its operation requires adequate patient dexterity. New surgical approaches include the male synthetic sling, which is emerging as a possible alternative. However, robust comparable data, derived from randomised controlled trials, on the relative safety and efficacy of the male synthetic sling and the artificial urinary sphincter are lacking.
We aimed to compare the clinical effectiveness and cost-effectiveness of the male synthetic sling with those of the artificial urinary sphincter surgery in men with persistent stress urinary incontinence after prostate surgery.
This was a multicentre, non-inferiority randomised controlled trial, with a parallel non-randomised cohort and embedded qualitative component. Randomised controlled trial allocation was carried out by remote web-based randomisation (1 : 1), minimised on previous prostate surgery (radical prostatectomy or transurethral resection of the prostate), radiotherapy (or not, in relation to prostate surgery) and centre. Surgeons and participants were not blind to the treatment received. Non-randomised cohort allocation was participant and/or surgeon preference.
The trial was set in 28 UK urological centres in the NHS.
Participants were men with urodynamic stress incontinence after prostate surgery for whom surgery was deemed appropriate. Exclusion criteria included previous sling or artificial urinary sphincter surgery, unresolved bladder neck contracture or urethral stricture after prostate surgery, and an inability to give informed consent or complete trial documentation.
We compared male synthetic sling with artificial urinary sphincter.
The clinical primary outcome measure was men's reports of continence (assessed from questions 3 and 4 of the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form) at 12 months post randomisation (with a non-inferiority margin of 15%). The primary economic outcome was cost-effectiveness (assessed as the incremental cost per quality-adjusted life-year at 24 months post randomisation).
In total, 380 men were included in the randomised controlled trial ( = 190 in each group), and 99 out of 100 men were included in the non-randomised cohort. In terms of continence, the male sling was non-inferior to the artificial urinary sphincter (intention-to-treat estimated absolute risk difference -0.034, 95% confidence interval -0.117 to 0.048; non-inferiority = 0.003), indicating a lower success rate in those randomised to receive a sling, but with a confidence interval excluding the non-inferiority margin of -15%. In both groups, treatment resulted in a reduction in incontinence symptoms (as measured by the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form). Between baseline and 12 months' follow-up, the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form score fell from 16.1 to 8.7 in the male sling group and from 16.4 to 7.5 in the artificial urinary sphincter group (mean difference for the time point at 12 months 1.30, 95% confidence interval 0.11 to 2.49; = 0.032). The number of serious adverse events was small (male sling group, = 8; artificial urinary sphincter group, = 15; one man in the artificial urinary sphincter group experienced three serious adverse events). Quality-of-life scores improved and satisfaction was high in both groups. Secondary outcomes that showed statistically significant differences favoured the artificial urinary sphincter over the male sling. Outcomes of the non-randomised cohort were similar. The male sling cost less than the artificial sphincter but was associated with a smaller quality-adjusted life-year gain. The incremental cost-effectiveness ratio for male slings compared with an artificial urinary sphincter suggests that there is a cost saving of £425,870 for each quality-adjusted life-year lost. The probability that slings would be cost-effective at a £30,000 willingness-to-pay threshold for a quality-adjusted life-year was 99%.
Follow-up beyond 24 months is not available. More specific surgical/device-related pain outcomes were not included.
Continence rates improved from baseline, with the male sling non-inferior to the artificial urinary sphincter. Symptoms and quality of life significantly improved in both groups. Men were generally satisfied with both procedures. Overall, secondary and post hoc analyses favoured the artificial urinary sphincter over the male sling.
Participant reports of any further surgery, satisfaction and quality of life at 5-year follow-up will inform longer-term outcomes. Administration of an additional pain questionnaire would provide further information on pain levels after both surgeries.
This trial is registered as ISRCTN49212975.
This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in ; Vol. 26, No. 36. See the NIHR Journals Library website for further project information.
前列腺手术后男性常出现压力性尿失禁,且难以改善。植入人工尿道括约肌是治疗持续性压力性尿失禁最常用的手术方法,但需要专业的手术技能,且可能需要进行多次修订。此外,该括约肌相对昂贵,其操作需要患者具备足够的灵巧度。新的手术方法包括男性合成吊带,它正成为一种可能的替代方法。然而,缺乏来自随机对照试验的关于男性合成吊带和人工尿道括约肌在前列腺手术后持续性压力性尿失禁男性患者中的相对安全性和有效性的可靠可比数据。
我们旨在比较男性合成吊带与人工尿道括约肌治疗前列腺手术后持续性压力性尿失禁男性患者的临床效果和成本效益。
这是一项多中心、非劣效性随机对照试验,同时进行了平行非随机队列和嵌入式定性部分。通过远程基于网络的随机化(1∶1)、以前的前列腺手术(前列腺根治性切除术或经尿道前列腺切除术)、放疗(与前列腺手术相关或不相关)和中心进行随机对照试验分配。外科医生和参与者均不知道所接受的治疗。非随机队列分配基于参与者和/或外科医生的偏好。
该试验在英国国民保健署的 28 个英国泌尿科中心进行。
该试验纳入了因前列腺手术而患有尿动力学压力性尿失禁且认为手术合适的男性患者。排除标准包括先前的吊带或人工尿道括约肌手术、前列腺手术后膀胱颈挛缩或尿道狭窄未解决、无法给予知情同意或完成试验文件。
我们比较了男性合成吊带与人工尿道括约肌。
男性报告的尿控情况(通过尿失禁咨询国际会议问卷-尿失禁短表的问题 3 和 4 评估)是 12 个月随机分组后的主要临床结局(非劣效性边界为 15%)。主要的经济结局是成本效益(通过 24 个月随机分组后的增量成本-质量调整生命年评估)。
共有 380 名男性被纳入随机对照试验(每组 190 名),99 名男性被纳入非随机队列。在尿控方面,男性吊带不劣于人工尿道括约肌(意向治疗估计绝对风险差异-0.034,95%置信区间-0.117 至 0.048;非劣效性=0.003),这表明接受吊带治疗的成功率较低,但置信区间排除了非劣效性边界-15%。在两组中,治疗都导致了尿失禁症状的减少(通过尿失禁咨询国际会议问卷-尿失禁短表评估)。从基线到 12 个月随访,男性吊带组的尿失禁咨询国际会议问卷-尿失禁短表评分从 16.1 降至 8.7,人工尿道括约肌组从 16.4 降至 7.5(12 个月时的时间点平均差异为 1.30,95%置信区间 0.11 至 2.49;=0.032)。严重不良事件的数量较少(男性吊带组=8;人工尿道括约肌组=15;人工尿道括约肌组中有一名男性发生了 3 次严重不良事件)。两组的生活质量评分均有所提高,且满意度较高。显示统计学差异的次要结局均有利于人工尿道括约肌。非随机队列的结果相似。男性吊带的成本低于人工括约肌,但与较小的质量调整生命年获益相关。与人工尿道括约肌相比,男性吊带的增量成本效益比表明,每失去一个质量调整生命年可节省 425870 英镑。在愿意支付 30000 英镑的质量调整生命年的意愿阈值下,男性吊带具有成本效益的概率为 99%。
没有超过 24 个月的随访数据。没有包括更具体的手术/器械相关疼痛结局。
从基线开始,尿控率得到改善,男性合成吊带与人工尿道括约肌非劣效。两组的症状和生活质量均显著改善。男性通常对两种手术都满意。总体而言,次要和事后分析均倾向于人工尿道括约肌优于男性合成吊带。
参与者报告的任何进一步手术、满意度和 5 年随访时的生活质量将提供更长期的结果。实施额外的疼痛问卷将提供有关两种手术后疼痛水平的进一步信息。
本试验在英国国家卫生与保健优化研究所(NIHR)卫生技术评估计划下注册,将在;第 26 卷,第 36 期。有关该项目的更多信息,请访问 NIHR 期刊库网站。